Table 2.
Factors associated with the GMI >1.33
| Parameters | Categories | GMI > 1.33 n (%) | Odds ratio (OR, 95% CI) | P value |
|---|---|---|---|---|
| Age | <52 | 38 (27.9) | 0.90 (0.54; 1.51) | 0.6954 |
| ≥52 | 43 (30.1) | 1 | ||
| Tumor grade | Other | 48 (32.2) | 1 | 0.2108 |
| High | 33 (25.4) | 1.40 (0.83–2.36) | ||
| Histological subtypes | Lipo- and Leiomyo-sarcomas | 64 (31.4) | 1.56 (0.84–2.89) | 0.1576 |
| Other subtypes | 17 (22.7) | 1 | ||
| Performance status (Eastern Cooperative Oncology Group, ECOG) | 0 | 48 (35.0) | 1.76 (1.04–2.98) | 0.0388 |
| 1 & 2 | 33 (23.4) | 1 | ||
| Ifosfamide | No prior treatment | 14 (28.6) | 0.97 (0.49–1.92) | 0.9378 |
| Prior treatment | 67 (29.1) | 1 | ||
| Dacarbazine | No prior treatment | 65 (29.0) | 1.00 (0.52–1.91) | 0.9915 |
| Prior treatment | 16 (29.1) | 1 | ||
| Gemcitabine | No prior treatment | 71 (29.8) | 1.32 (0.61–2.83) | 0.4794 |
| Prior treatment | 10 (24.4) | 1 | ||
| Number of previous lines of chemotherapy | 1 | 41 (28.9) | 0.98 (0.59; 1.65) | 0.9525 |
| ≥2 | 40 (29.2) | 1 | ||
| Lung metastasis | Absence | 34 (33.7) | 1.41 (0.83–2.4) | 0.2001 |
| Presence | 47 (26.4) | 1 | ||
| Liver metastasis | Absence | 59 (28.4) | 0.91 (0.50–1.64) | 0.7425 |
| Presence | 21 (30.4) | 1 | ||
| Bone metastasis | Absence | 73 (28.5) | 0.75 (0.30–1.84) | 0.5270 |
| Presence | 8 (34.8) | 1 | ||
| Other metastases | Absence | 25 (29.4) | 1.03 (0.59–1.80) | 0.9262 |
| Presence | 56 (28.9) | 1 | ||
| Hemoglobin (g/dl) | <12 | 35 (28.9) | 0.98 (0.58; 1.66) | 0.9458 |
| ≥12 | 46 (29.3) | 1 | ||
| Albumin (g/l) | <35 | 8 (19.5) | 0.52 (0.23; 1.18) | 0.1171 |
| ≥35 | 72 (31.9) | 1 |
GMI, growth modulation index.